Correction: YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma

Molecular Cancer 2026 Open access

Read full text
Authors: Jian Kong, Fandong Kong, Gao Ji, Qiangbo Zhang, ShuYing Dong, Fang Gu, Shan Ke, Bing Pan, Qiang Shen, Huichuan Sun, Lemin Zheng, Wenbing Sun
DOI: 10.1186/s12943-025-02565-7
Cited by: 0
References: 1

Abstract

Following the publication of the original article [1], the authors noticed that in Figure 2D the image of caspase 9 for BEL-7402 cells was inadvertently duplicated from the adjacent HepG2 caspase 9 panel, and the image of Actin for BEL-7402 was misused.They wish to formally request an erratum to rectify this issue.In the correct Figure 2, provided below, they have updated the correct Figure 2D.They are confident that the inadvertent panel duplication did not have any effect on their analyses or on any conclusions drawn from the paper, and they apologize for the error. Molecular CancerThe original article can be found online at h t t p s : / / d o i . o r g / 1 0 . 1 1 8 6 / 1 4 7 6 -4 5 9 8 -1 3 -7.

Fields of Study & Subjects

Hepatocellular Carcinoma Treatment and Prognosis Cytokine Signaling Pathways and Interactions Liver physiology and pathology

Publication details

Journal / source
Molecular Cancer
Volume
25
Issue
1
Pages
12–12
Publication date
12 January 2026
Language
EN